| Names | |
|---|---|
| Preferred IUPAC name | 2-acetyloxybenzoic acid; (2S)-2,6-diaminohexanoic acid |
| Other names | Lysine acetylsalicylate Acetylsalicylate lysine Lys-ASA DL-K-ASA |
| Pronunciation | /ˌdiːˌɛlˈlaɪsiːn əˌsiːtɪl.səˈlɪ.sɪ.leɪt/ |
| Identifiers | |
| CAS Number | 5749-67-7 |
| Beilstein Reference | 1073347 |
| ChEBI | CHEBI:9027 |
| ChEMBL | CHEMBL1201211 |
| ChemSpider | 55158 |
| DrugBank | DB09213 |
| ECHA InfoCard | 03b4b80c-5e78-4e86-8c9b-c5f945cb0d97 |
| EC Number | 8007-27-2 |
| Gmelin Reference | 77256 |
| KEGG | C14325 |
| MeSH | D02.241.223.560.500.300 |
| PubChem CID | 6603864 |
| RTECS number | AJ4025000 |
| UNII | 8F8WA41P0T |
| UN number | 2811 |
| CompTox Dashboard (EPA) | DTXSID60915995 |
| Properties | |
| Chemical formula | C16H24N2O6 |
| Molar mass | 337.38 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.325 g/cm³ |
| Solubility in water | Freely soluble |
| log P | -2.0 |
| Acidity (pKa) | 9.9 |
| Basicity (pKb) | pKb: 5.0 |
| Magnetic susceptibility (χ) | -6.2e-6 cm³/mol |
| Refractive index (nD) | 1.583 |
| Dipole moment | 6.31 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of DL-Lysine Acetylsalicylate: 321.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | −1497.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3703 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | B01AC06 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS05 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P305+P351+P338, P362+P364, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Autoignition temperature | Autoignition temperature: 410°C (770°F) |
| Lethal dose or concentration | LD₅₀ (oral, rat): 1100 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral 1,100 mg/kg |
| NIOSH | MV6138500 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for DL-Lysine Acetylsalicylate: Not established. |
| REL (Recommended) | 600 mg |
| IDLH (Immediate danger) | N.D. |
| Related compounds | |
| Related compounds | Aspirin Lysine Sodium acetylsalicylate Calcium acetylsalicylate |
| Product Identification | Manufacturer Technical Commentary |
|---|---|
|
Product Name: DL-Lysine Acetylsalicylate IUPAC Name: 2-Acetoxybenzoic acid, compound with 2,6-diaminohexanoic acid (1:1) Chemical Formula: C15H22N2O6 Synonyms & Trade Names: Lysine acetylsalicylate; Acetylsalicylic acid lysinate; Aspirin lysine complex HS Code & Customs Classification: 29182190 (dependent on national regulations) |
In direct manufacturing, the exact nomenclature used in documentation always tracks back to analytical records and batch books. The IUPAC name helps to align with regulatory agencies when registering import or export, and the systematic structure description is referenced in technical transfer projects. For chemical formula designation, production documents use the neutral compound molecular formula to facilitate raw material tracking and yield calculations at the batch level. Synonyms in the manufacturing plant refer both to internal process naming conventions and registered product catalog identities. Trade names and alternate synonyms often relate to downstream use sectors—pharmaceutical excipients, injectable preparations, or intermediate processing require different procurement validation. Export documentation references the HS code chosen according to the specific chemical function; for this intermediate, the anabolic pathway and functional carboxylate/salicylate identification are used to match the “salts and esters of salicylic acid” bracket. Customs classification always depends on the regional customs office and the final declared end-use. Compositional differences between pharma and non-pharma grades may influence subheading choice, and supporting technical dossiers may be requested by border compliance officers. Technical users should confirm which harmonized tariff schedule and regulatory notes apply for their sector and geography. |
In manufacturing, DL-Lysine acetylsalicylate typically forms as a crystalline, off-white to pale yellow solid. Color and clarity often reflect both the upstream purification efficiency and care in preventing thermal decomposition during drying steps. Slight odor can originate from residual acetic acid or salicylate; odor intensity signals process cleanliness.
Observed melting behavior fluctuates depending on grade; production control focuses on narrowing melting range as broader ranges often indicate the presence of unreacted lysine or acetylsalicylic acid. Decomposition may precede melting if exposed to excessive heat, particularly beyond typical low- to mid-100°C, so thermal ramp rates in analytical testing are closely monitored. No practical boiling point due to decomposition before boiling.
As a high-molecular salt with no significant volatility at room temperature, flash point determination isn't operationally relevant. Density values, measured for bulk handling calibration, depend on the degree of particle aggregation and moisture control, with apparent density rising under hygroscopic or caked conditions.
Hydrolysis can occur in humid environments, particularly under elevated temperature or alkaline conditions. Acyl migration and partial hydrolysis by water or trace bases result in assay drift and appearance of degradation impurities; this reinforces the use of controlled humidity in both processing and storage.
Product dissolves readily in water; solubility can vary with temperature, pH, and counter-ion ratio in specialty grades. Solution preparation must avoid local overheating and must achieve full dissolution before sterile filtration in parenteral or high-purity applications, as undissolved solids can indicate quality drift.
Specification ranges for DL-Lysine acetylsalicylate depend on intended use—pharmaceutical grades differ from food-additive or industrial grades mainly by impurity thresholds, microbial limits, and pyrogen management. Analytical evaluation aligns with outlined grade requirements; no universal standard due to regional and customer-specific monographs.
Main impurities stem from incomplete neutralization, side-chain hydrolysis, or raw material carryover (salicylic acid, acetic acid, lysine excess). Each batch undergoes HPLC or titrimetric analysis tailored to the impurity profiles targeted for the commercial grade. Limits align with pharmacopeia where required or are driven by customer specifications.
Lab protocols reference compendial assays where possible; deviation from pharmacopeia occurs to address customer-specific sensitivity or selectivity issues in downstream formulation. Non-compendial methods are validated in alignment with ICH and internal QA/QC rationale.
Production demand for high-purity DL-lysine and acetylsalicylic acid inputs, with specific screening for unwanted trace metals and microbiological contaminants, especially in parenteral grades. Supplier agreements enforce consistency on these incoming quality attributes.
Manufacture involves neutralizing acetylsalicylic acid with DL-lysine in aqueous or controlled alcohol media. Process variables focus on pH control, stoichiometric balance, and minimizing thermal exposure so as to suppress acyl migration and maintain assay.
Key controls include reaction endpoint by titration, recrystallization media selection, and robust washing to minimize mother liquor residue. Solid-liquid separation and drying are maintained under inert or low-moisture atmospheres. Impurity removal effectiveness governs product grade differentiation.
Batch consistency checks blend in-process monitoring (pH, conductivity, filtration clarity) and final product assays for appearance, solubility, assay, impurity profile, and microbial burden. Release criteria reflect both regulatory monographs and end-user requirements; no product is released without full specification conformance matched to its designated grade.
In formulation or modification, DL-Lysine acetylsalicylate acts as a salicylate donor or participates in salt/exchange reactions. Hydrolysis to constituent lysine and acetylsalicylic acid occurs under base or aqueous stress and modification to alternative salts, or esters is feasible under controlled conditions.
Reactivity varies with solvent, pH, and temperature; catalysts rarely required. Manufacturers monitor these variables to avoid undesired hydrolysis, particularly during process scale-up or custom derivative synthesis.
Current industrial use focuses on direct utilization, but potential exists for conversion to other amino acid–salicylate salts, or further derivatization in API synthesis. Modification is application- and customer-specific, often under proprietary or contract terms with tailored process parameters.
Routine storage employs cool, low-humidity warehousing, with active humidity and temperature monitoring for sensitive or high-purity grades. Avoidance of direct light and air helps prevent hydrolytic and oxidative change. Inert gas blanket adopted during extended storage for highest-purity material.
Container selection prioritizes compatibility with mildly acidic or hygroscopic material; HDPE drums or lined fiberboard containers provide reliable barrier protection. For sensitive grades, double-bagging and airtight seals reduce water ingress and microbiological risk.
Shelf life reflects exposure sensitivities; manufacturers track color shift, increased moisture content, odor changes, and assay drop-off as early indicators of degradation. Release programs specify retest intervals rather than fixed expiry dates when supplied to custom or regulated applications.
Hazard classification depends on the grade’s intended use and national submission criteria. Manufacturers align labels and documentation with chemically analogous substances (salicylates), applying precautionary measures for dust generation and moisture contact.
Operator guidance covers respiratory, dermal, and ocular protection; inadvertent exposure risks mirror those of amino acid salts and salicylates. Spill and cleanup procedures focus on containing powder and controlling exposure to water.
Toxicological profile reflects both the lysine and acetylsalicylate components. Acute toxicity and chronic exposure data reference literature for structurally similar compounds, with customer requests addressed on a case-by-case basis for additional toxicological investigation or residue analysis.
Workplace exposures managed according to local regulatory limits for comparable active pharmaceutical ingredients, applying dust control, ventilation, and operator training. Product is handled using closed transfer and contained milling systems in higher-risk contexts.
Manufacturing of DL-Lysine Acetylsalicylate depends heavily on both the availability of qualified precursor materials and operational scheduling in multipurpose synthesis plants. Batch consistency is managed through continuous in-process checks, especially for batch crystallization and final purification. Supply continuity can fluctuate during periods of raw lysine or salicylic acid feedstock constraint, or following routine plant maintenance shutdowns. In peak operational mode, supply scales with downstream demand signals from pharmaceutical-grade buyers, with industrial grades running on alternate lines if technical resources are available.
Typical lead time, driven by both batch reactor campaign planning and purification plant scheduling, ranges from several weeks for standard pharmaceutical grade to shorter periods for technical grade when demand is stable. MOQ is determined by the scale of final batch splits and solid-handling logistics; bulk quantities benefit from direct discharge, with smaller lots subject to packing schedule co-ordination.
DL-Lysine Acetylsalicylate packaging varies by grade and destination. Pharmacy-intermediate and injectable grades require high-barrier liner bags within fiber drums under validated cleanroom conditions. Technical applications use lined bags, composite drums, or sacks based on downstream blend requirements. For export, the packaging specification is finalized after route risk assessment and temperature excursion protection planning.
Sea and air shipment both form part of the standard logistics mix, with temperature and humidity management specified in contract terms for regulated markets. Payment terms are subject to credit approval and contract type, with letters of credit or advance payment often required for new customers or emerging market destinations.
The price is dictated by the cost share of lysine base (typically from bio-fermentation), acetylsalicylic acid, solvent, and purification agents such as activated carbon and buffer salts. Upward movement in fermentation feedstocks (corn syrup, ammonia, specialty enzymes) propagates through. Salicylic acid costs follow seasonal fluctuations in phenol and toluene markets, with price shocks linked to specialty chemical supply interruptions or regional plant turnarounds.
Short-term price swings occur from crude oil derivative volatility (influencing solvents), tariff or non-tariff market disruptions, and new registration requirements for active pharmaceutical ingredients in leading import markets. Supply chain tightening during logistics slowdowns, such as port congestion or long customs clearing times in import-dependent markets, also contributes to periodic cost surges.
Final product pricing carries a significant premium for GMP-compliant, injectable, or high-purity pharmaceutical grades, reflecting intensive process control, documentation costs, and added facility qualification steps. Purity level influences both regulatory acceptance and downstream yield efficiency. Packaging certified under USP or EU pharmacopeial monograph standards supports higher end-use claims and triggers higher unit costs compared to industrial grades shipped in non-certified containers.
Asia, particularly China and India, anchors global supply due to robust fermentation infrastructure and tight salicylic acid value chain integration. Demand pulls from North America, Europe, and Japan track innovation cycles in anti-inflammatory and antithrombotic therapy pipeline expansion. Supply disruptions in any major region can rapidly re-route demand and cause pricing divergence.
United States and European Union exhibit stable offtake at the pharmaceutical grade, with regulatory audit requirements restricting supply to a small number of qualified producers. Japan maintains strict import control on active ingredients, affecting the market entry of non-audited sources. China and India not only lead global exports but also act as swing markets capable of generating surplus or drawing heavily from global inventory pools based on local policy shifts or temporary facility shutdowns.
Forecasts for 2026 suggest continued pressure from rising feedstock and energy costs along with stricter environmental compliance for chemical synthesis, especially in China and the EU. Post-pandemic normalization is expected to gradually ease extreme spot-market fluctuations but incremental price increases for pharmaceutical and GMP grades will likely persist. Data for this forecast derives from material cost indices, energy pricing trends, public manufacturer earnings reports, and customer sourcing surveys.
Internal forecasts aggregate input from plant-level raw material purchase records, global chemical feedstock indices, government chemical sector bulletins, and market surveillance by the logistics and regulatory affairs teams. Price signals from quarterly customer tenders and forward contract quotations also feature in methodology translation for year-on-year cost evolution.
Major manufacturers responded to recent plant closures in Europe and North Asia by shifting campaign runs to alternate sites and re-prioritizing core customers for medical and parenteral applications. Efforts to improve solvent recovery and energy efficiency have accelerated, with several facilities trialing waste heat integration and advanced crystallization control to sustain competitive output.
Regulatory agencies in both the EU and US updated inspection protocols for active pharmaceutical ingredient (API) suppliers, with increased focus on process traceability and impurity profiling. Trace contaminant thresholds and documentation requirements now more frequently dictate market acceptability than basic certificate of analysis results. In China, new emissions and workplace safety standards prompted temporary shutdowns in certain chemical districts, affecting export timelines.
Process intensification, digital batch traceability, and multi-level release documentation underpin quality assurance. Suppliers prioritized export batches for longstanding audit-cleared clients and implemented adaptive risk management—adjusting campaign scheduling to buffer order commitments against local raw material or logistics shocks. Expanded engagement with third-party auditors and participation in cross-border pharma quality consortia ensure ongoing regulatory alignment for 2026 and beyond.
DL-Lysine Acetylsalicylate, produced in bulk and fine chemicals plants, serves as a key raw material in several sectors. In the pharmaceutical industry, its water solubility and bioavailability support use in analgesic and antipyretic formulations, including injectable preparations where rapid dissolution is essential. In veterinary medicine, the compound finds use where alternative administration routes or specific pharmacokinetics are required. Other applications include research reagents and specialty chemical intermediates, where compound purity and performance directly affect downstream results.
| Grade | Characteristic Features | Typical Applications |
|---|---|---|
| Pharmaceutical Grade | Low residual solvents, stringent microbial controls, controlled heavy metals profile, typically micro-pulverized or fine crystalline; batch documentation to allow regulatory submission. | Human drug formulations, parenteral products, oral and topical pharmaceuticals. |
| Veterinary Grade | Purity standards tailored to animal health requirements, broader impurity profile acceptance, larger crystal size acceptable. | Animal health products, veterinary drug formulations. |
| Technical or Laboratory Grade | Relaxed impurity control, focus on practical performance, may allow higher residual starting material, manufactured with reduced process buffer zones. | Reagent supply, chemical intermediates, non-pharmaceutical R&D. |
The main properties affecting suitability: active content, water solubility, residual solvent levels, heavy metal content, particle size, and microbiological count. For pharmaceutical injectables, particle size uniformity, API load, and low endotoxin burden form critical compliance parameters. In solid dose applications, flowability and compressibility affect processing outcomes. For veterinary or technical grades, physical consistency and meeting internal QC standards remain the focus, with release specifications tailored by use case.
Identify whether use falls under regulated human or veterinary pharmaceutical, chemical processing, or R&D. Application scope strongly influences the grade selection process, as each sector sets distinct criteria for allowable impurities, biological load, and batch traceability.
Check applicable pharmacopoeias and regulatory submissions, such as EP, USP, or national authorities. Pharmaceutical applications demand defined impurity limits, validated analytical methods, and batch release testing aligned with submission dossiers. Veterinary and laboratory users may apply internal or regional guidance as best practice.
Determine process sensitivity to trace impurities, excipient compatibility, and physical form. Tight impurity specifications, especially for solvents and degradation byproducts, are often required for injectables or oral dose pharmaceuticals. Laboratory grades may tolerate higher non-critical impurity content, where performance, not regulatory limits, guides suitability.
Higher grades call for tighter raw material selection, increased purification cycles, and extensive in-process quality monitoring. These measures support compliance but raise production cost per kilogram. Large-scale technical applications may prioritize supply continuity and batch-to-batch consistency at lower cost, favoring process grades with relaxed documentation.
Process-specific compatibility testing remains essential. Production runs with representative material from the specified grade allow assessment under intended conditions, uncovering unforeseen formulation or stability concerns. Manufacturer support teams evaluate feedback together with in-process control data to adjust future batches if required.
Manufacturing DL-Lysine Acetylsalicylate at scale calls for a controlled environment guided by practical quality management systems. Most customers in regulated segments reference international standards for assurance. Facility approvals and compliance documentation (such as ISO standards) directly impact the release of each batch. Audit-ready systems—covering raw material reception through to final QC—help safeguard traceability across multiple production shifts and campaigns. Adjustments or upgrades in quality management originate either from changes in regulations or new customer audit findings, not as a matter of routine procedure.
Certification requirements for DL-Lysine Acetylsalicylate revolve around its intended use. Pharmaceutical applications call for adherence to pharmacopeial references or specific monographs, subject to regional regulatory frameworks. For non-pharma or intermediate grades, conformance to customer-defined purity targets and impurity profiles dominate. Certifiable aspects—microbial purity, specified residues, or allergen status—vary significantly by destination and final formulation. Consistent documentation, including statements on BSE/TSE, GMO, or residual solvents, will usually trail each fresh certificate-of-analysis, not just at first supply.
Customers demand current batch documentation, not archived or desktop samples. Each delivery is accompanied by a batch-specific certificate of analysis based on in-house or accredited third-party laboratory results. Requests for extended reports—stability data, technical dossiers, or supply chain traceability—depend on project phase and regulatory review cycle. Document disclosures always observe confidentiality rules linked to both the synthetic route and source material. Periodic process revalidation or regulatory retesting can lead to updated documentation across the entire lot release protocol.
Supporting long-term procurement means running campaigns matched to both historic order profiles and emerging customer forecasts. Core capacity is managed through both fixed production lines and contingency expansion margins, minimizing disruptions. Contingency stock and staggered production scheduling help reduce lead times during seasonal or market-driven demand surges. When a major customer requires safety stock or short-notice deliveries, production planning is adjusted accordingly—not simply by pushing queues, but by realigning raw material reservations and equipment allocations.
Industrial DL-Lysine Acetylsalicylate requires a commitment to lot-to-lot consistency. The plant’s installed capacity and historical campaign yields factor into any scheduling dialogue. Factors influencing capacity utilization include raw material purity, plant maintenance schedules, and regulatory changeovers. Continuous dialogue with buyers cuts the risks of under-supply or excess inventory, especially for critical customers with single-source dependency.
Sample requests link directly to the intended application and regulatory expectations. For pharmaceutical and food-grade inquiries, full traceability and documented release standards are required before dispatch. Inquiry handling checks both legal restrictions and internal release criteria. Samples reflect either validated production batches or pilot lots, depending on the development stage. Feedback loops from sample appraisal guide further production tweaks or quality adjustments before full-scale supply.
Procurement models shift in response to supply chain shifts, project timelines, and regulatory signals from buyers. Framework agreements tend to dominate long-range supply relationships, with defined supply windows and rolling call-offs. For customers facing unpredictable market conditions, flexible contract terms—covering call-off volumes, buffer inventories, and consignment stock—can be set up. Emergency orders or priority manufacturing slots are considered under contingency protocols, weighed against pipeline stability and cross-customer demand. All adjustments align with both shipment lead times and factory scheduling discipline. Quarterly review cycles recalibrate terms as needed, rather than sticking to fixed templates.
Recent R&D investments in DL-Lysine Acetylsalicylate concentrate on improving solubility characteristics and achieving more consistent bioavailability profiles, especially for injectable and oral pharmaceutical grades. Several groups have explored co-crystallization with various excipients to address moisture sensitivity during formulation and storage. Attention has shifted toward minimizing residual organic solvents and controlling particle size distribution, since both factors directly impact the filtration and dissolution rates in downstream formulation.
Novel medical applications continue to gain traction, particularly for pediatric and geriatric formulations where mild taste and improved gastrointestinal tolerance offer advantages over conventional acetylsalicylates. Some R&D teams are investigating its integration into combination therapies targeting acute pain and inflammation where rapid onset and low-gastric-irritation profiles are prioritized. Outside direct pharmaceutical use, technical grades are being evaluated for veterinary formulations, especially where animal feed or supplement solubility proves challenging using base acetylsalicylate forms.
Moisture and oxidative stability remain persistent obstacles, particularly in humid climate zones and bulk storage. Purity levels above pharmacopeial minimums require close control of acetic acid and lysine-related impurities, which often arise during synthesis and downstream purification. Some manufacturers have implemented continuous monitoring at critical process points to limit variability between lots, but uniformity in crystal habit and minimization of fines calls for further process optimization. Notably, in-process modifications to neutralization conditions and selection of lysine isomer mixtures have produced measurable improvements in dissolution speed and final filterability.
Based on pharmaceutical sector expansion and tightening standards surrounding excipient profiles, demand for DL-Lysine Acetylsalicylate with enhanced flowability and lower residual solvent content is projected to increase. Growth will likely be strongest in regions aligning regulatory definitions with stringent impurity and endotoxin thresholds, particularly throughout Asia-Pacific and select EU markets. Animal health applications are anticipated to raise requirements for technical-grade consistency and trace impurity disclosure, with some producers already fielding requests for custom specification matching.
Process routes will likely shift further toward aqueous or hybrid solvent systems aimed at reducing emissions and measurable organic residues. Feedback-driven adjustments to temperature, pH, and filtration control are expected to play a larger role, resulting in more reliable batch-to-batch consistency and narrower specification windows. Producers are investing in analytics that offer real-time impurity profiling to preempt off-spec rework and flag trend deviations before release.
Raw material sourcing strategies have shifted focus toward renewable feedstocks and reduction in high-impact reagents. Some lines have adopted closed-loop solvent recovery, aiding alignment with local and global emissions guidelines. Suppliers are increasingly asked to provide transparency around each input’s environmental footprint—a consideration with direct impact on downstream audits and customer acceptance in global supply chains.
Process and R&D teams support partners from specification review to final product application. Recommendations are tailored according to customer’s target formulation process—whether high-shear granulation, direct compression, or aqueous reconstitution. Analytical data relevant to critical solvent, impurity, and particle size attributes can be provided on request, with interpretive guidance available for comparison to local pharmacopeial limits or industry benchmarks.
Field technical teams advise on blending strategies to minimize dusting, segregation, and agglomeration, taking into account grade-specific particle size and moisture content. Where a process challenge relates to solubility, flow, or filter plugging, samples from alternate synthesis routes can be provided to inform trial scale-up. Direct engagement with formulator or site technical staff accelerates troubleshooting, especially when unique carrier or excipient combinations are involved.
All shipped material includes product documentation referencing the controlling internal release criteria. Retain samples are kept for all released tons to support later analysis or investigate any quality-related concerns. In the event of deviation or customer-reported nonconformity, response prioritizes both root cause investigation and replacement material provision, per contract terms. Ongoing supply involves continuous dialogue regarding quality targets, raw material changes, or process improvement efforts—inclusive of quarterly or annual technical review meetings with long-term customers.
Our DL-Lysine Acetylsalicylate production runs from in-house synthesis, where we control every step from raw material acquisition to final drying and packing. This direct approach lets us achieve tight lot-to-lot consistency — an absolute requirement for manufacturers relying on reproducible performance. Each batch follows an established process protocol, supporting traceability in regulated environments. Strict adherence to our internal standards means end-users can plan formulation and process validation with confidence.
DL-Lysine Acetylsalicylate has found adoption in pharmaceutical intermediate manufacturing, effervescent tablet technology, and veterinary preparations. It acts as a stable salt for active pharmaceutical ingredients and supports the formulation of buffered aspirin products where optimized solubility and rapid disintegration matter. Beyond human healthcare, feed and animal health specialists value its blendability and compatibility with broad solvent systems.
Every batch leaving our facility undergoes a sequence of chemical analysis, including quantitative lysine and acetylsalicylate verification and impurity profiling. Retained samples from every lot allow retrospective examination, providing a documented quality chain for downstream users. By investing in on-premises QC labs, we reduce release times and prevent logistical delays for volume buyers.
Bulk production capability gives us flexibility in packaging formats. We supply DL-Lysine Acetylsalicylate in fiber drums with inner liners, multi-ply bags, and bespoke container solutions suitable for large-scale processing plants. Our experienced logistics team manages regulatory documentation and arranges for full-container shipments or smaller repeat deliveries as project timelines require. With regular output, customers secure consistent supply streams, reducing the risk of raw material gaps.
Industrial clients can expect direct engineering support for any questions on product handling, pre-mix compatibility, and process integration. Our technical team partners with plant managers and R&D teams during scale-up, troubleshooting, or analytical comparison between batches. This direct engineering interface gives buyers practical information to optimize process yields and manage compliance risk.
Procurement teams benefit from multi-year production stability and the transparency of dealing directly with the producer. Distributors expanding their branded ingredient lines gain from secure, managed supply and batch-specific documentation. Manufacturers running cost-sensitive or large-volume operations have confidence in supply continuity and clear communication regarding product availability and scheduling.
By handling every aspect of production and delivery, we enable our buyers to minimize operational risks and administrative overhead. Our expertise in DL-Lysine Acetylsalicylate manufacturing supports downstream innovation, regulatory compliance, and long-term business planning. Clients gain access to a partner with clear accountability and proven capacity in amino acid derivative manufacturing.
Working daily on the production line with DL-Lysine Acetylsalicylate, our team deals with its unique properties at scale and guides customers through every practical challenge this substance brings up. This direct engagement, from synthesis to quality control, gives us firsthand insight beyond textbook definitions.
Our product appears as a white to almost white, crystalline powder. This uniformity in appearance results from stringent manufacturing protocols, helping users in high-spec applications, where clarity and consistency matter for downstream processing or formulation. DL-Lysine Acetylsalicylate is essentially a lysine salt of acetylsalicylic acid, resulting in an ionic structure that delivers distinct physicochemical behaviors compared to acetylsalicylic acid alone.
The powder has a reliable melting point, which helps signal purity and proper synthesis conditions. In our facility, precise temperature controls, monitored by automated systems, keep this material stable and reproducible, and our in-process checking covers all batches leaving the reactor.
Chemically, its salt form with lysine provides a buffering effect. Users notice improved stability in aqueous applications and enhanced performance in protocols where plain aspirin would show hydrolytic breakdown. We made these adjustments years ago to meet modern demands in pharmaceutical and chemical research.
One of the driving factors behind our switch to lysine acetylsalicylate was its superior solubility. Aspirin’s limited dissolution rate in water restricts its uses outside of standard tablet formulations. By contrast, DL-Lysine Acetylsalicylate dissolves well in water, forming a clear solution, which enables applications in fast-dissolving formulations and solutions where immediate bioavailability or rapid processing is important. Users do not encounter clumping or extended stirring, reducing both labor and material losses in pilot and production environments.
In direct tests, our technical team routinely prepares aqueous solutions to confirm transparency and dissolution rates. This attribute allows our customers to formulate oral and parenteral solutions more efficiently than with standard acetylsalicylic acid.
We do not recommend dissolving this compound in non-polar solvents like hexane or ether as these offer practically no solubility. These observations come from years of bench-scale experiments, not from literature reviews, and we tailor our technical support to the realities of customer operations.
Our partners from the pharmaceutical and research sectors request materials that can shrink process times, streamline formulation steps, and lower the risk of variable performance. The improved solubility profile means fewer filtration steps and less time waiting for solutions to clarify. The salt’s chemical stability under typical storage and handling conditions means less waste and a longer usable shelf life, aligning with good manufacturing practice (GMP) principles. We back every shipment with batch-level data on appearance, melting point, and solubility, as we know unexpected variation can translate to thousands of dollars lost in downstream operations.
For direct technical queries, our staff includes chemists who have synthesized and purified this compound in-house. We provide firsthand advice grounded in our own process experience—not generic answers copied from public fact sheets. Detailed analytical data and supportive testing methods are available to our qualified customers whenever needed.
Anyone looking to source DL-Lysine Acetylsalicylate on a commercial scale typically wants fast, clear answers about minimum order quantity and available packaging. We manufacture this compound directly in our own facility. From raw materials selection to final packing, we oversee every stage, so our approach to MOQ and packaging fits actual production, storage, and logistics constraints—not marketing guesswork or reseller markups.
MOQ reflects our need to run production batches efficiently. Each production cycle involves equipment setup, waste minimization, solvent recovery, and compliance checks. Costs and time rise sharply for small lots, and international logistics favor full-pallet or container loads. For our standard offer, MOQ for DL-Lysine Acetylsalicylate generally begins at 25 kilograms—one full fiber drum or carton. This batch size matches factory workflow and helps keep costs competitive. Pharmaceutical, food, and fine chemical customers often order at this scale or higher. Orders below 25 kg would cost disproportionately more per kilo due to setup and handling overhead; we rarely find such requests feasible outside of special R&D programs or sample shipments.
Our standard packaging has evolved after years of customer feedback and logistics data. Fiber drums (each containing 25 kg of product) made with food-grade liners provide robust protection from moisture, contaminants, and physical damage. The drum seals tightly so the material can cross continents by ship, rail, or truck without loss of quality. In some cases, we supply double PE-lined bags for bulk clients. These typically hold 10 kg or 20 kg, but always within robust outer cartons to ensure stability during pallet stacking and transport. All cartons and drums are shrink-wrapped for extra security and label integrity.
We understand the diverse requirements among formulation teams—some large pharmaceutical plants want several metric tons in one lot, while others conducting pilot trials value smaller, well-packaged units for easy inventory control. By default, 25 kg fiber drums remain the workhorse across our customer base. For confirmed long-term partners with specialized needs, we have implemented custom packaging—smaller quantities in sealed aluminum foil pouches, for example—though these come with additional production steps and material costs.
Facility logistics also play a direct role. Fiber drums stack safely on pallets and move easily by forklift, helping warehouse teams minimize accidents or spills. Smaller bags suit laboratories, but in factory or distribution settings, too many small packs can create stock-keeping headaches. Our technical team works closely with large-volume users to plan optimal batch and delivery schedules, streamlining everything from dock unloading to end-use dispensing. We run regular stability and compatibility testing on all our packaging to prevent migration, absorption, or degradation during typical transit periods.
Because we handle direct manufacturing and oversee every shipment, our product packaging and MOQ policy stems from practical realities, not just commercial convention. When we see recurring demands for certain sizes or formats, we adapt packaging lines accordingly after technical review. Our aim is to deliver DL-Lysine Acetylsalicylate in fresh, secure, and usable units—without unnecessary storage, transport, or administrative complications that drive up the final per-kilo cost for customers. We can provide detailed technical documentation for clients who require traceability or audit support on packaging materials and batch histories.
Shipping chemicals globally is not a formality—it is a process that places safety, transparency, and responsibility at the core of every shipment. As the manufacturer, we see firsthand how thorough documentation impacts safe handling and seamless customs clearance. International customers and logistics partners require a clear chain of trust, and certifications like Material Safety Data Sheets (MSDS) and Certificates of Analysis (COA) have become expectations, not exceptions.
We prepare every MSDS in accordance with globally recognized formats, including GHS (Globally Harmonized System), reflecting the specific properties of each batch. Our team compiles these based on rigorous hazard identification, handling advice, emergency procedures, and regulatory references. Precise details on composition, first aid, storage, and disposal signal to our clients that we take both operational transparency and on-site safety seriously. Our downstream customers in industrial manufacturing, pharmaceuticals, agriculture, and other regulated sectors rely on these documents to train personnel and implement site-wide safety measures.
A COA accompanies every shipment leaving our facilities. We align these certificates directly with our QC lab analysis, matching each batch number and shipment. Every value—purity, moisture, particle size, or any relevant chemical property—stems from controlled in-house testing, not assumptions. We do not release product for export without our QA team’s signature that confirms the COA. The international market—especially in the Americas, Europe, and APAC—demands this documentation, as regulations in many jurisdictions block entry without it.
Customs agents, regulatory bodies, and freight carriers each assess shipping documents against country-specific requirements. An incomplete or outdated MSDS causes real-world issues: border delays, fines, or—even worse—emergency mishandling. Technical data that is not batch-specific draws doubts about compliance from end users, particularly in industries with strict controls like food, personal care, and electronics. Our approach is to maintain current documentation, review regulatory changes, and respond immediately to client requests for additional certification or local language translation.
Emerging rules, such as updated REACH requirements in the European Union or changes in the US TSCA Inventory, prompt us to adjust both our documentation templates and internal compliance checks. We invest in continuous training for our regulatory compliance managers and conduct regular audits to ensure alignment with new global standards. Our regulatory team participates in industry consortia to monitor changes and update clients—so no shipment moves without confidence in its paperwork.
We provide serialized documentation for every order shipped, along with digital access to safety sheets and COAs. Whether an end user requests TDS, origin certificates, or proof of compliance with food or pharma standards, our technical support group responds swiftly. We maintain document retention consistent with global record-keeping requirements and supply documentation in English or translated as needed.
Every customer deserves the certainty that comes from factory-direct documentation. Our certificates and data sheets speak to the precision and accountability of our manufacturing. We view regulatory compliance as an ongoing partnership with our clients—one that builds trust while keeping people and supply chains safe across borders.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
